Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ohad Atia

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
European Journal of Pediatrics|July 6, 2026
Disease severity of children with hereditary spherocytosis predicts the clinical course of aplastic crisisShiri Rubin, Shira Devora Ben Ami, Ohad Atia, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2025
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort studyOhad Atia, Zivia Shavit-Brunschwig, Raffi Lev-Tzion, et al.
Journal of Crohn'S & Colitis|January 12, 2022
Existing Prediction Models of Disease Course in Paediatric Crohn's Disease Are Poorly Replicated in a Prospective Inception CohortOhad Atia, Ben Kang, Esther Orlansky-Meyer, et al.
Inflammatory Bowel Diseases|February 8, 2024
Predictors of Complicated Disease Course in Adults and Children With Crohn's Disease: A Nationwide Study from the epi-IIRNOhad Atia, Rona Lujan, Rachel Buchuk, et al.
Journal of Crohn'S & Colitis|September 19, 2025
Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort studyOmer Rotem-Tryfus, Ben Kang, Esther Orlanski-Meyer, et al.
The Lancet. Gastroenterology & Hepatology|October 28, 2022
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort studyOhad Atia, Zivia Shavit-Brunschwig, Diane R Mould, et al.
Inflammatory Bowel Diseases|May 20, 2024
Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis: A Nationwide Study From the epi-IIRNOhad Atia, Rachel Buchuk, Rona Lujan, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2022
Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mixOhad Atia, Gemma Pujol-Muncunill, Víctor Manuel Navas-López, et al.
Journal of Crohn'S & Colitis|November 18, 2021
Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics-A Nationwide Study From the Epi-IIRNOhad Atia, Esther Orlanski-Meyer, Rona Lujan, et al.
Crohn'S & Colitis 360|February 13, 2023
Development and Validation of the IBD-REFER Criteria: Early Referral for Suspected Inflammatory Bowel Diseases in Adults and ChildrenOhad Atia, Adi Shosberger, Gili Focht, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Pediatrics|July 6, 2026
Disease severity of children with hereditary spherocytosis predicts the clinical course of aplastic crisisShiri Rubin, Shira Devora Ben Ami, Ohad Atia, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2025
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort studyOhad Atia, Zivia Shavit-Brunschwig, Raffi Lev-Tzion, et al.
Journal of Crohn'S & Colitis|January 12, 2022
Existing Prediction Models of Disease Course in Paediatric Crohn's Disease Are Poorly Replicated in a Prospective Inception CohortOhad Atia, Ben Kang, Esther Orlansky-Meyer, et al.
Inflammatory Bowel Diseases|February 8, 2024
Predictors of Complicated Disease Course in Adults and Children With Crohn's Disease: A Nationwide Study from the epi-IIRNOhad Atia, Rona Lujan, Rachel Buchuk, et al.
Journal of Crohn'S & Colitis|September 19, 2025
Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort studyOmer Rotem-Tryfus, Ben Kang, Esther Orlanski-Meyer, et al.
The Lancet. Gastroenterology & Hepatology|October 28, 2022
Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort studyOhad Atia, Zivia Shavit-Brunschwig, Diane R Mould, et al.
Inflammatory Bowel Diseases|May 20, 2024
Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis: A Nationwide Study From the epi-IIRNOhad Atia, Rachel Buchuk, Rona Lujan, et al.
Alimentary Pharmacology & Therapeutics|June 23, 2022
Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mixOhad Atia, Gemma Pujol-Muncunill, Víctor Manuel Navas-López, et al.
Journal of Crohn'S & Colitis|November 18, 2021
Improved Outcomes of Paediatric and Adult Crohn's Disease and Association With Emerging Use of Biologics-A Nationwide Study From the Epi-IIRNOhad Atia, Esther Orlanski-Meyer, Rona Lujan, et al.
Crohn'S & Colitis 360|February 13, 2023
Development and Validation of the IBD-REFER Criteria: Early Referral for Suspected Inflammatory Bowel Diseases in Adults and ChildrenOhad Atia, Adi Shosberger, Gili Focht, et al.
Pageof 4